Abbott
Lonza to make Elan’s Alzheimer’s candidate
December 7, 2011Manufacturing and Production Abbott, Elan, Lonza
Elan has awarded a manufacturing contract to Lonza to supply the active pharmaceutical ingredient (API) for its small-molecule candidate Alzheimer’s …
Abbott expands diagnostic pact with GlaxoSmithKline
November 29, 2011Research and Development, Sales and Marketing Abbott, Cancer, GSK, non-small cell lung cancer
Abbott will develop a diagnostic kit for GlaxoSmithKline’s new lung cancer drug candidate. This is an expansion of a …
Abbott spin-off could attract mega merger
October 21, 2011Research and Development, Sales and Marketing Abbott, Bayer, Humira, Merck, Roche
Abbott’s new spin-off pharma firm could attract a lot of attention from big pharma looking to sure up their portfolios. …
Abbott to split into two separate companies
October 20, 2011Manufacturing and Production, Research and Development, Sales and Marketing Abbott, Abbott Laboratories
Abbott’s management has decided to split the company into two separate entities in order to give shareholders a ‘distinct investment …
New MS drug shows promise for Abbott
August 10, 2011Research and Development, Sales and Marketing Abbott, Avonex, Biogen, MS, gilenya
Biogen and Abbott’s multiple sclerosis drug daclizumab has performed well in a mid-stage trial, but two deaths marred the overall …
Abbott wins $1.7bn Humira case
February 24, 2011Sales and Marketing Abbott, Abbott Laboratories, Centocor, Johnson and Johnson, Remicade, Simponi, TNF, golimumab, infliximab, rheumatoid arthritis
Abbott has been saved from paying Johnson & Johnson $1.7 billion after a US appeals court quashed a patent dispute …
Abbott hep C drug ABT-450/r impresses in mid-stage trial
November 2, 2010Research and Development ABT-450/r, Abbott, Abbott Laboratories, American Liver Disease congress, Enanta Pharmaceuticals, Norvir, hepatitis C
Mid-stage trial results of Abbott Laboratories’ oral hepatitis C drug ABT-450/r have impressed at the American Liver Disease congress. The …
Abbott withdraws anti-obesity drug amid safety worries
October 11, 2010Sales and Marketing Abbott, Meridia, obesity
Abbott has pulled its anti-obesity drug Meridia in the US after recent trials showed it increased the risk of stroke …
Recipharm buys Abbott plant to enter Spanish market
October 5, 2010Manufacturing and Production Abbott, Recipharm, Solvay
Swedish contract development and manufacturing services company Recipharm has agreed to buy a facility in Parets del Valles, Spain, from …
Abbott’s Meridia ‘increases heart attack risk’
September 2, 2010Sales and Marketing Abbott, Meridia, drug safety
Abbott’s weight-loss drug Meridia increases the risk of stroke and heart attack in patients with heart disease, according a study …
Abbott boosted by Solvay integration
July 22, 2010Sales and Marketing 2010 financials, Abbott, Q2, Solvay
Abbott has posted a set of strong sales for the second quarter, buoyed by the integration of Solvay Pharmaceuticals and …
Olivier Bohuon joins Pierre Fabre
July 16, 2010Sales and Marketing Abbott, Pierre Fabre, appointment, sales and marketing
Olivier Bohuon is to replace Jean-Pierre Garnier as the head of French pharma company Pierre Fabre from September. Bohuon is …
Abbott and Daiichi Sankyo acclaimed in great places to work survey
May 31, 2010Business Services Abbott, Daiichi Sankyo
The Great Place to Work Institute has named Abbott as one of the Top 50 Best Workplaces in the UK, …
Abbott starts head-to-head MS trial
May 25, 2010Research and Development, Sales and Marketing Abbott, Avonex, Biogen, Gilena, daclizumab
Abbott has started enrolment for a phase III trial of daclizumab, a once-monthly injection for relapsing-remitting multiple sclerosis that it …
Latest content
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
Phoenix Labs acquires Kent Pharma
Astoriom acquires Sampled’s UK stability storage operations
Alcami appoints Will Isom to lead laboratory services sales
